Cannabis Investing Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
Cannabis Investing Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Cannabis Investing Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Cannabis Investing Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Cannabis Investing Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Cannabis Investing Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Cannabis Investing Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Cannabis Investing Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
Cannabis Investing Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
Seegnal's operating subsidiary Seegnal E-Health Ltd. hires AI VP to Strengthen AI Capabilities and Accelerates Development of Seegnal Guard
